Investigating how cell death proteins affect inflammation in sepsis
Official title: Cell death proteins as inflammatory mediators in sepsis
Funded at Emory University · NIH-11094066 · Data updated 2026-11-12
This study is looking at how certain cell signals related to cell death affect inflammation in people with sepsis, a serious infection, to help find better treatments for those who are suffering from it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $391,250 |
| NIH project number | 5R35GM151220-03 |
| Project ID | NIH-11094066 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with sepsis or those at high risk of developing sepsis due to severe infections.
✕Less likely to help
Patients with non-infectious causes of critical illness or those not experiencing sepsis may not benefit from this research.
What this research studies
This research focuses on understanding the role of cell death signaling pathways in the inflammatory response associated with sepsis, a severe condition triggered by infection. By analyzing samples from septic patients, the study aims to uncover how these pathways contribute to inflammation and tissue damage. The research employs both laboratory techniques and patient data to explore the mechanisms behind sepsis, which could lead to the development of targeted therapies. The ultimate goal is to improve treatment options for patients suffering from this critical illness.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for sepsis, improving patient outcomes and reducing mortality rates.
How similar studies have gone: Previous research has shown promise in understanding inflammatory responses in sepsis, but this specific approach focusing on cell death proteins is relatively novel.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Lyons, John Daniel — Emory University
- Study coordinator: Lyons, John Daniel
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.